Description
Product Usage Information
Dibutyryl-cAMP (sodium salt) is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 1.02 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles .
Background
Dibutyryl-cAMP (sodium salt), also known as bucladesine, is an analog of the second messenger cyclic adenosine 3'5'-monophosphate (cAMP). Dibutyryl-cAMP is a phosphodiesterase (PDE) inhibitor and a cAMP-dependent protein kinase (PKA) activator that mimics the action of cAMP in cells (1). The anti-inflammatory activity of Dibutyryl-cAMP makes it an option for the treatment of skin inflammation (2). Exposure of rat glial cells to Dibutyryl-cAMP inhibited cell growth and increased glial fibrillary acidic protein levels, resulting in a change toward an astrocytic phenotype (3). Treatment of rat hepatocytes with Dibutyryl-cAMP suppressed both iNOS mRNA and protein expression, decreased iNOS promoter activity, and reduced DNA binding of the transcription factor NF-κB (4). Dibutyryl-cAMP treatment increased phosphorylated cAMP-response element-binding protein (p-CREB) via protein kinase A (PKA) signaling in rat pulmonary fibroblasts. Cells treated with Dibutyryl-cAMP exhibited a reduced number and size of silicosis nodules, and inhibited myofibroblast differentiation and extracellular matrix deposition (5).
Alternate Names
Bucladesine Na; N 6 ,O2' -Dibutyryl adenosine 3',5'-cyclic monophosphate sodium salt
